Supplemental Benefit of an ARB in Hypertensive Patients With Stable Heart Failure Using Olmesartan | Clinical Trial - SUPPORT


The goal of the trial was to evaluate treatment with olmesartan compared with control among hypertensive patients with chronic heart failure (CHF) on a background therapy of angiotensin-converting enzyme (ACE) inhibitors, beta-blockers, or both.

Contribution to the Literature: The SUPPORT trial showed that the addition of olmesartan to standard heart failure therapy (ACE inhibitors and beta-blockers) increased adverse events.